CytomX Therapeutics PE Ratio 2014-2021 | CTMX

Current and historical p/e ratio for CytomX Therapeutics (CTMX) from 2014 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. CytomX Therapeutics PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

CytomX Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 5.48 0.00
2021-06-30 6.33 $-1.19 0.00
2021-03-31 7.73 $-1.23 0.00
2020-12-31 6.55 $-0.71 0.00
2020-09-30 6.65 $-1.19 0.00
2020-06-30 8.33 $-1.39 0.00
2020-03-31 7.67 $-1.69 0.00
2019-12-31 8.31 $-2.26 0.00
2019-09-30 7.38 $-2.19 0.00
2019-06-30 11.22 $-2.20 0.00
2019-03-31 10.75 $-1.91 0.00
2018-12-31 15.10 $-2.00 0.00
2018-09-30 18.50 $-1.26 0.00
2018-06-30 22.86 $-1.01 0.00
2018-03-31 28.45 $-1.35 0.00
2017-12-31 21.11 $-1.18 0.00
2017-09-30 18.17 $-1.59 0.00
2017-06-30 15.50 $-1.71 0.00
2017-03-31 17.27 $-1.41 0.00
2016-12-31 10.99 $-1.62 0.00
2016-09-30 15.68 $-1.62 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.352B $0.100B
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86